211 related articles for article (PubMed ID: 30024511)
1. Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib: A retrospective cohort study.
Tang J; Zhao R; Zheng X; Xu L; Wang Y; Feng L; Ren S; Wang P; Zhang M; Xu M
Medicine (Baltimore); 2018 Jul; 97(29):e11400. PubMed ID: 30024511
[TBL] [Abstract][Full Text] [Related]
2. Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study.
Qianyi W; Mei X; Rui Z; Yong W; Yutao W; Xiaoding S; Xiaoting W
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1493-1500. PubMed ID: 34319443
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
Fu Y; Hao H; Guo L; Yang G; Zhang X
Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
[TBL] [Abstract][Full Text] [Related]
4. Development and external validation of a nomogram for individualized adjuvant imatinib duration for high-risk gastrointestinal stromal tumors: A multicenter retrospective cohort study.
Liu R; Wu Y; Gong J; Zhao R; Li L; Wan Q; Lian N; Shen X; Xia L; Shen Y; Xiao H; Wu X; Chen Y; Cen Y; Xu X
Cancer Med; 2022 Aug; 11(16):3093-3105. PubMed ID: 35297216
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
Joensuu H; Eriksson M; Hall KS; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Ballman KV; Leinonen M; DeMatteo RP; Reichardt P
Cancer; 2014 Aug; 120(15):2325-33. PubMed ID: 24737415
[TBL] [Abstract][Full Text] [Related]
6. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
Wu X; Li J; Xu W; Gao J; Li Y; Shen L
Future Oncol; 2018 Jul; 14(17):1721-1729. PubMed ID: 29969914
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
[TBL] [Abstract][Full Text] [Related]
9. Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.
Cavnar MJ; Wang L; Balachandran VP; Antonescu CR; Tap WD; Keohan M; Singer S; Temple L; Nash GM; Weiser MR; Guillem JG; Aguilar JG; DeMatteo RP; Paty PB
Ann Surg Oncol; 2017 Dec; 24(13):3972-3980. PubMed ID: 29058144
[TBL] [Abstract][Full Text] [Related]
10. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
11. [Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study].
Zhang P; Zhang J; Zhang B; Yang WC; Hu JB; Sun XF; Zhai G; Qian HR; Li Y; Xu H; Feng F; Wu XY; Liu HL; Liu HJ; Qiu HB; Wu XJ; Zhou YB; Shen KT; Kou YW; Fu Y; Jie ZG; Zou XM; Cao H; Gao ZD; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):775-782. PubMed ID: 34530558
[No Abstract] [Full Text] [Related]
12. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study.
Vincenzi B; Napolitano A; Fiocco M; Mir O; Rutkowski P; Blay JY; Reichardt P; Joensuu H; Fumagalli E; Gennatas S; Hindi N; Nannini M; Spalato Ceruso M; Italiano A; Grignani G; Brunello A; Gasperoni S; De Pas T; Badalamenti G; Pantaleo MA; van Houdt WJ; IJzerman NS; Steeghs N; Gelderblom H; Desar IME; Falkenhorst J; Silletta M; Sbaraglia M; Tonini G; Martin-Broto J; Hohenberger P; Le Cesne A; Jones RL; Dei Tos AP; Gronchi A; Bauer S; Casali PG
Clin Cancer Res; 2022 Apr; 28(8):1672-1679. PubMed ID: 34615721
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.
Zhao WY; Xu J; Wang M; Zhang ZZ; Tu L; Wang CJ; Cao H; Zhang ZG
BMC Gastroenterol; 2014 Jun; 14():105. PubMed ID: 24906683
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
[No Abstract] [Full Text] [Related]
15. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
Lin JX; Chen QF; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Huang CM
J Cancer Res Clin Oncol; 2017 Apr; 143(4):727-734. PubMed ID: 28083710
[TBL] [Abstract][Full Text] [Related]
16. The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy.
Guerin A; Sasane M; Gauthier G; Keir CH; Zhdavana M; Wu EQ
J Med Econ; 2015 Mar; 18(3):241-8. PubMed ID: 25422992
[TBL] [Abstract][Full Text] [Related]
17. Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: Retrospective analysis of an International Patient Registry.
Stuart E; Banerjee S; de la Torre J; Wang Y; Scherzer N; Burgoyne AM; Parry L; Fanta PT; Ramamoorthy S; Sicklick JK
J Surg Oncol; 2019 Sep; 120(4):715-721. PubMed ID: 31297829
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach.
Conley AP; Guérin A; Sasane M; Gauthier G; Schwiep F; Keir CH; Wu EQ
J Gastrointest Cancer; 2013 Jun; 44(2):190-8. PubMed ID: 23229801
[TBL] [Abstract][Full Text] [Related]
19. Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras.
Cavnar MJ; Seier K; Curtin C; Balachandran VP; Coit DG; Yoon SS; Crago AM; Strong VE; Tap WD; Gönen M; Antonescu CR; Brennan MF; Singer S; DeMatteo RP
Ann Surg; 2021 Jan; 273(1):128-138. PubMed ID: 30946076
[TBL] [Abstract][Full Text] [Related]
20. Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.
Ihle MA; Huss S; Jeske W; Hartmann W; Merkelbach-Bruse S; Schildhaus HU; Büttner R; Sihto H; Sundby Hall K; Eriksson M; Reichardt P; Joensuu H; Wardelmann E
PLoS One; 2018; 13(2):e0193048. PubMed ID: 29451912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]